Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
Dimitrios PapadopoulosDimos-Dimitrios D MitsikostasPublished in: CNS drugs (2019)
With all of the oral DMTs examined, R-MS patients are more likely to achieve NEDA than experience any adverse event.
Keyphrases
- multiple sclerosis
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- ankylosing spondylitis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- white matter
- juvenile idiopathic arthritis
- mass spectrometry
- prognostic factors
- peritoneal dialysis
- electronic health record
- patient reported outcomes
- adverse drug